HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis.

Abstract
Switching to a glycolytic metabolism is a rapid adaptation of tumor cells to hypoxia. Although this metabolic conversion may primarily represent a rescue pathway to meet the bioenergetic and biosynthetic demands of proliferating tumor cells, it also creates a gradient of lactate that mirrors the gradient of oxygen in tumors. More than a metabolic waste, the lactate anion is known to participate to cancer aggressiveness, in part through activation of the hypoxia-inducible factor-1 (HIF-1) pathway in tumor cells. Whether lactate may also directly favor HIF-1 activation in endothelial cells (ECs) thereby offering a new druggable option to block angiogenesis is however an unanswered question. In this study, we therefore focused on the role in ECs of monocarboxylate transporter 1 (MCT1) that we previously identified to be the main facilitator of lactate uptake in cancer cells. We found that blockade of lactate influx into ECs led to inhibition of HIF-1-dependent angiogenesis. Our demonstration is based on the unprecedented characterization of lactate-induced HIF-1 activation in normoxic ECs and the consecutive increase in vascular endothelial growth factor receptor 2 (VEGFR2) and basic fibroblast growth factor (bFGF) expression. Furthermore, using a variety of functional assays including endothelial cell migration and tubulogenesis together with in vivo imaging of tumor angiogenesis through intravital microscopy and immunohistochemistry, we documented that MCT1 blockers could act as bona fide HIF-1 inhibitors leading to anti-angiogenic effects. Together with the previous demonstration of MCT1 being a key regulator of lactate exchange between tumor cells, the current study identifies MCT1 inhibition as a therapeutic modality combining antimetabolic and anti-angiogenic activities.
AuthorsPierre Sonveaux, Tamara Copetti, Christophe J De Saedeleer, Frédérique Végran, Julien Verrax, Kelly M Kennedy, Eui Jung Moon, Suveera Dhup, Pierre Danhier, Françoise Frérart, Bernard Gallez, Anthony Ribeiro, Carine Michiels, Mark W Dewhirst, Olivier Feron
JournalPloS one (PLoS One) Vol. 7 Issue 3 Pg. e33418 ( 2012) ISSN: 1932-6203 [Electronic] United States
PMID22428047 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Hypoxia-Inducible Factor 1
  • Monocarboxylic Acid Transporters
  • RNA, Small Interfering
  • Symporters
  • monocarboxylate transport protein 1
  • fibroblast growth factor 13
  • Lactic Acid
  • Fibroblast Growth Factors
  • Luciferases
  • Vascular Endothelial Growth Factor Receptor-2
Topics
  • Analysis of Variance
  • Animals
  • Blotting, Western
  • Cell Movement (physiology)
  • Endothelial Cells (metabolism, physiology)
  • Enzyme-Linked Immunosorbent Assay
  • Fibroblast Growth Factors (metabolism)
  • Humans
  • Hypoxia-Inducible Factor 1 (metabolism)
  • Immunohistochemistry
  • Lactic Acid (metabolism, pharmacology)
  • Luciferases
  • Mice
  • Monocarboxylic Acid Transporters (metabolism)
  • Neoplasms (blood supply)
  • Neovascularization, Pathologic (metabolism)
  • Nuclear Magnetic Resonance, Biomolecular
  • Polymerase Chain Reaction
  • RNA Interference
  • RNA, Small Interfering (genetics)
  • Symporters (metabolism)
  • Vascular Endothelial Growth Factor Receptor-2 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: